Imvax

IHC-001 Clin0 hepatocellular carcinoma; IEC-001 Clin0 endometrial cancer; IUC-001 Clin0 urothelial cancer; IOC-001 Clin0 ovarian cancer

Immvax is developing personalized, whole tumor-derived immunotherapies for solid tumors. The company has a proprietary Goldspire platform, which captures the full antigen signature of the tumor by using a lysate of the patient's own tumor cells. This ensures that the patient's immune system is exposed to all of the different antigens present on the tumor cells. The platform also stimulates both the innate and adaptive immune system. The innate immune system is the first line of defense against infection and cancer. The adaptive immune system is the more specific and long-lasting arm of the immune system. By stimulating both the innate and adaptive immune system, the Goldspire platform helps to overcome the immunosuppressive tumor microenvironment.

Jobs: